Clinical Trial – Friday Pop Quiz 6/5
The patient developed this cutaneous adverse event 2 weeks after starting a clinical trial medication. What is the mechanism of action of the culprit medication?
A. Epidermal growth factor receptor (EGFR) inhibitor
B. Tumor necrosis factor (TNF)-alpha inhibitor
C. Smoothened inhibitor
D. BRAF inhibitor
E. Programmed cell death (PD)-1 inhibitor
To find out the correct answer and …
The patient developed this cutaneous adverse event 2 weeks after starting a clinical trial medication. What is the mechanism of action of the culprit medication?
A. Epidermal growth factor receptor (EGFR) inhibitor
B. Tumor necrosis factor (TNF)-alpha inhibitor
C. Smoothened inhibitor
D. BRAF inhibitor
E. Programmed cell death (PD)-1 inhibitor
To find out the correct answer and … 
The patient declines surgical intervention for this cutaneous neoplasm and a decision is made to pursue medical therapy.
What is the most common side effect of the FDA-approved medication for this cutaneous neoplasm?
A.) Nausea
B.) Flu-like illness
C.) Chest pain
D.) Muscle spasms
E.) Alopecia
To find out the correct answer a … 